Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.043
Neutral
RSI(14)
42.422
Neutral
STOCH(KDJ)(9,3,3)
46.973
Neutral
ATR(14)
0.257
Low Volatility
CCI(14)
-90.062
Neutral
Williams %R
65.306
Sell
TRIX(12,20)
-0.484
Sell
StochRSI(14)
4.461
Sell
BioLine RX Ltd
BLRX3.640USD
-0.110-2.93%
Close 09/03, 16:00（ET）Quotes delayed by 15 min
9.31BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-02Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
26.000
Target Price
+586.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.94M.
Overvalued
The company’s latest PE is -536.48, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 197.43K shares, decreasing 32.14% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Financial Health
Currency: USD Updated：2025-09-02The company's current financial score is 7.93, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 255.00K, representing a year-over-year decrease of 96.28%, while its net profit experienced a year-over-year decrease of 836.64%.
Score
Financials
9.40
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
8.58
Operational Efficiency
7.36
Growth Potential
7.31
Shareholder Returns
6.97
Company Valuation
Currency: USD Updated：2025-09-02The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -526.47, which is 32.83% below the recent high of -699.30 and -99.98% above the recent low of -1052.82.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 166/689
No Data
Earnings Forecast
Currency: USD Updated：2025-09-02The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for BioLine RX Ltd is 26.00, with a high of 40.00 and a low of 12.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
2
analysts
Buy
Current Rating
26.000
Target Price
+593.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
BioLine RX Ltd
BLRX
2
CRISPR Therapeutics AG
CRSP
30
Intellia Therapeutics Inc
NTLA
27
Ionis Pharmaceuticals Inc
IONS
27
Exact Sciences Corp
EXAS
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-02The company’s current price momentum score is 4.98, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 4.12 and the support level at 3.30, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.700
Sell
MA10
3.699
Sell
MA20
3.728
Sell
MA50
4.133
Sell
MA100
3.942
Sell
MA200
5.182
Sell
Institutional Confidence
Currency: USD Updated：2025-09-02The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 4.63%, representing a quarter-over-quarter increase of 7.70%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
No Data
Risk Assessment
Currency: USD Updated：2025-09-02The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 2.96, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 1.25. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.25
VaR
+7.47%
240-Day Maximum Drawdown
+90.84%
240-Day Volatility
+139.00%
Return
Best Daily Return
60 days
+13.76%
120 days
+38.50%
5 years
+52.98%
Worst Daily Return
60 days
-11.34%
120 days
-21.90%
5 years
-40.87%
Sharpe Ratio
60 days
-0.22
120 days
+0.83
5 years
-0.26
Risk Assessment
Maximum Drawdown
240 days
+90.84%
3 years
+97.52%
5 years
+98.76%
Return-to-Drawdown Ratio
240 days
-0.93
3 years
-0.30
5 years
-0.19
Skewness
240 days
-0.81
3 years
-0.36
5 years
+0.36
Volatility
Realised Volatility
240 days
+139.00%
5 years
+106.40%
Standardised True Range
240 days
+21.38%
5 years
+112.19%
Downside Risk-Adjusted Return
120 days
+150.83%
240 days
+150.83%
Maximum Daily Upside Volatility
60 days
+72.40%
Maximum Daily Downside Volatility
60 days
+52.13%
Liquidity
Average Turnover Rate
60 days
+0.01%
120 days
+0.03%
5 years
--
Turnover Deviation
20 days
-97.33%
60 days
-93.56%
120 days
-68.42%
Peer Comparison
Currency: USD Updated：2025-09-02BioLine RX Ltd
BLRX
5.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
7.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
7.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
7.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
